Involvement of all-trans-retinoic acid in the breakdown of retinoic acid receptors alpha and gamma through proteasomes in MCF-7 human breast cancer cells

Citation
T. Tanaka et al., Involvement of all-trans-retinoic acid in the breakdown of retinoic acid receptors alpha and gamma through proteasomes in MCF-7 human breast cancer cells, BIOCH PHARM, 61(11), 2001, pp. 1347-1355
Citations number
30
Categorie Soggetti
Pharmacology & Toxicology
Journal title
BIOCHEMICAL PHARMACOLOGY
ISSN journal
00062952 → ACNP
Volume
61
Issue
11
Year of publication
2001
Pages
1347 - 1355
Database
ISI
SICI code
0006-2952(20010601)61:11<1347:IOAAIT>2.0.ZU;2-0
Abstract
Most studies have reported an up-regulation of retinoic acid receptor (RAR) mRNA expression by all-trans retinoic acid (RA). We aimed to study the eff ect of RA on RAR protein levels in MCF-7 human breast cancer cells. Incubat ion of these cells with 10(-6) M RA induced a rapid breakdown of both RAR a lpha and RAR gamma in spite of the accumulation of their mRNAs. Proteasome specific inhibitors blocked the RA-induced breakdown of RARs. Furthermore, RA enhanced the formation of the complex between RARa: and ubiquitin in a c oncentration and time-dependent manner, suggesting the involvement of ubiqu itin and proteasome in this reaction. Retinoid X receptor cu (RXR alpha) wa s also decreased, albeit to a lesser extent, in RA-treated cells. Use of sy nthetic receptor agonists and antagonists clearly showed that the effect of the retinoid on the breakdown of the retinoid receptors is receptor-ligand agonist-dependent and blunted by the antagonist. An electrophoretic mobili ty shift assay, using nuclear extracts from RA-treated cells, showed that a reduction in complex formation with hormone response elements correlated w ith the reduction of RAR and RXR protein. These data suggest that RA induce s the breakdown of RARs through a process involving ubiquitination and that this phenomenon causes a reduction in the formation of DNA-receptor comple xes. (C) 2001 Elsevier Science Inc. All rights reserved.